↓ Skip to main content

A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors

Overview of attention for article published in Journal of Hematology & Oncology, June 2014
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (55th percentile)
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

patent
2 patents

Citations

dimensions_citation
81 Dimensions

Readers on

mendeley
117 Mendeley